Tubize-Fin (TUB) - Net Assets

Latest as of December 2025: €1.89 Billion EUR ≈ $2.20 Billion USD

Based on the latest financial reports, Tubize-Fin (TUB) has net assets worth €1.89 Billion EUR (≈ $2.20 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.93 Billion ≈ $2.26 Billion USD) and total liabilities (€48.58 Million ≈ $56.79 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Tubize-Fin liquidity resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets €1.89 Billion
% of Total Assets 97.49%
Annual Growth Rate 5.96%
5-Year Change -41.93%
10-Year Change -3.68%
Growth Volatility 17.86

Tubize-Fin - Net Assets Trend (2000–2025)

This chart illustrates how Tubize-Fin's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Tubize-Fin for the complete picture of this company's asset base.

Annual Net Assets for Tubize-Fin (2000–2025)

The table below shows the annual net assets of Tubize-Fin from 2000 to 2025. For live valuation and market cap data, see TUB market cap.

Year Net Assets Change
2025-12-31 €1.89 Billion
≈ $2.20 Billion
+2.45%
2024-12-31 €1.84 Billion
≈ $2.15 Billion
+2.44%
2023-12-31 €1.80 Billion
≈ $2.10 Billion
+2.57%
2022-12-31 €1.75 Billion
≈ $2.05 Billion
-46.05%
2021-12-31 €3.25 Billion
≈ $3.80 Billion
+16.25%
2020-12-31 €2.79 Billion
≈ $3.27 Billion
+4.83%
2019-12-31 €2.66 Billion
≈ $3.11 Billion
+13.88%
2018-12-31 €2.34 Billion
≈ $2.74 Billion
+10.58%
2017-12-31 €2.12 Billion
≈ $2.47 Billion
+8.08%
2016-12-31 €1.96 Billion
≈ $2.29 Billion
+0.53%
2015-12-31 €1.95 Billion
≈ $2.28 Billion
+20.07%
2014-12-31 €1.62 Billion
≈ $1.90 Billion
+4.54%
2013-12-31 €1.55 Billion
≈ $1.81 Billion
+3.96%
2012-12-31 €1.49 Billion
≈ $1.74 Billion
-3.61%
2011-12-31 €1.55 Billion
≈ $1.81 Billion
+7.23%
2010-12-31 €1.44 Billion
≈ $1.69 Billion
+6.40%
2009-12-31 €1.36 Billion
≈ $1.59 Billion
+13.53%
2008-12-31 €1.20 Billion
≈ $1.40 Billion
-5.22%
2007-12-31 €1.26 Billion
≈ $1.47 Billion
-6.93%
2006-12-31 €1.36 Billion
≈ $1.58 Billion
+50.33%
2005-12-31 €901.39 Million
≈ $1.05 Billion
+52.12%
2004-12-31 €592.56 Million
≈ $692.76 Million
-6.67%
2003-12-31 €634.91 Million
≈ $742.27 Million
+10.10%
2002-12-31 €576.65 Million
≈ $674.17 Million
+11.23%
2001-12-31 €518.43 Million
≈ $606.10 Million
+16.91%
2000-12-31 €443.43 Million
≈ $518.42 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Tubize-Fin's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 18020523600.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings €180.21 Million 9.56%
Common Stock €235.00 Million 12.46%
Other Comprehensive Income €1.47 Billion 77.91%
Other Components €1.22 Million 0.06%
Total Equity €1.89 Billion 100.00%

Tubize-Fin Competitors by Market Cap

The table below lists competitors of Tubize-Fin ranked by their market capitalization.

Company Market Cap
News Corp A
NASDAQ:NWSA
$9.90 Billion
Jinduicheng Molybdenum Co Ltd
SHG:601958
$9.90 Billion
Antero Midstream Partners LP
NYSE:AM
$9.90 Billion
Shanghai International Airport Co Ltd
SHG:600009
$9.90 Billion
Viavi Solutions Inc
NASDAQ:VIAV
$9.89 Billion
Beijing Kunlun Tech Co Ltd
SHE:300418
$9.89 Billion
Gotion High tech Co Ltd
SHE:002074
$9.88 Billion
Smithfield Foods, Inc. Common Stock
NASDAQ:SFD
$9.88 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Tubize-Fin's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 1,840,405,526 to 1,885,559,936, a change of 45,154,410 (2.5%).
  • Net income of 93,228,016 contributed positively to equity growth.
  • Dividend payments of 46,315,000 reduced retained earnings.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income €93.23 Million +4.94%
Dividends Paid €46.31 Million -2.46%
Other Changes €-1.76 Million -0.09%
Total Change €- 2.45%

Book Value vs Market Value Analysis

This analysis compares Tubize-Fin's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 4.73x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 25.68x to 4.73x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2003-12-31 €7.80 €200.40 x
2004-12-31 €13.02 €200.40 x
2005-12-31 €20.21 €200.40 x
2006-12-31 €30.38 €200.40 x
2007-12-31 €28.27 €200.40 x
2008-12-31 €26.80 €200.40 x
2009-12-31 €30.42 €200.40 x
2010-12-31 €32.37 €200.40 x
2011-12-31 €34.71 €200.40 x
2012-12-31 €33.46 €200.40 x
2013-12-31 €34.78 €200.40 x
2014-12-31 €36.25 €200.40 x
2015-12-31 €43.71 €200.40 x
2016-12-31 €43.97 €200.40 x
2017-12-31 €47.50 €200.40 x
2018-12-31 €52.52 €200.40 x
2019-12-31 €418.02 €200.40 x
2020-12-31 €62.74 €200.40 x
2021-12-31 €72.94 €200.40 x
2022-12-31 €39.35 €200.40 x
2023-12-31 €40.36 €200.40 x
2024-12-31 €41.35 €200.40 x
2025-12-31 €42.36 €200.40 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Tubize-Fin utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 4.94%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 1.03x
  • Recent ROE (4.94%) is below the historical average (11.60%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2003 47.23% 54422.12% 0.00x 3.16x €93.09 Million
2004 20.91% 6195350.00% 0.00x 1.21x €64.65 Million
2005 32.60% 96.36% 0.30x 1.13x €203.72 Million
2006 35.22% 303.77% 0.10x 1.18x €341.77 Million
2007 3.13% 67.48% 0.03x 1.33x €-86.58 Million
2008 -0.08% -5.70% 0.01x 1.33x €-120.44 Million
2009 12.03% 90.97% 0.10x 1.27x €27.60 Million
2010 1.45% 55.99% 0.02x 1.24x €-123.53 Million
2011 4.18% 76.35% 0.05x 1.21x €-90.15 Million
2012 5.21% 83.87% 0.05x 1.20x €-71.43 Million
2013 3.98% 81.40% 0.04x 1.16x €-93.44 Million
2014 3.75% 84.99% 0.04x 1.13x €-101.34 Million
2015 10.91% 21252600.00% 0.00x 1.16x €17.79 Million
2016 9.26% 59995.36% 0.00x 1.14x €-14.57 Million
2017 13.52% 105.03% 0.12x 1.09x €74.37 Million
2018 12.19% 98.93% 0.12x 1.06x €51.20 Million
2019 10.65% 9456800.00% 0.00x 1.03x €17.27 Million
2020 9.33% 0.00% 0.00x 1.01x €-18.77 Million
2021 11.71% 0.00% 0.00x 1.01x €55.41 Million
2022 4.86% 1044901.09% 0.00x 1.05x €-89.99 Million
2023 4.91% 0.00% 0.00x 1.07x €-91.51 Million
2024 4.90% 679673.60% 0.00x 1.05x €-93.94 Million
2025 4.94% 0.00% 0.00x 1.03x €-95.33 Million

Industry Comparison

This section compares Tubize-Fin's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $732,069,496
  • Average return on equity (ROE) among peers: -22.60%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Tubize-Fin (TUB) €1.89 Billion 47.23% 0.03x $9.89 Billion
Argen-X (ARGX) $10.23 Million 0.00% 0.20x $42.08 Billion
BioSenic S.A. (BIOS) $-6.76 Million 0.00% 0.00x $1.57 Million
Celyad SA (CYAD) $90.88 Million -25.97% 0.53x $8.95 Million
Hyloris Developmentsen Sa (HYL) $39.07 Million -39.37% 0.22x $168.91 Million
Onward Medical N.V. (ONWD) $52.63 Million -62.27% 0.46x $184.65 Million
Oxurion NV (OXUR) $48.44 Million -32.97% 0.07x $311.42K
UCB SA (UCB) $4.89 Billion 2.35% 1.08x $51.74 Billion

About Tubize-Fin

BR:TUB Belgium Biotechnology
Market Cap
$10.43 Billion
€8.92 Billion EUR
Market Cap Rank
#2278 Global
#8 in Belgium
Share Price
€200.40
Change (1 day)
+0.10%
52-Week Range
€121.40 - €247.50
All Time High
€247.50
About

Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. It engages in discovering and developing treatments for patients suffering from serious illnesses that affect the immune system or the central nervous system. The company was incorporated in 1928 and is based in Brussels, Belgium.